|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
EP2314617B1
(en)
|
2004-07-23 |
2015-06-24 |
Acceleron Pharma Inc. |
ActRII receptor polypeptides
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
EA201692543A1
(ru)
|
2005-11-23 |
2017-08-31 |
Акселерон Фарма Инк. |
Антагонисты активина-actriia и их применение для стимулирования роста кости
|
|
WO2007130619A1
(en)
|
2006-05-03 |
2007-11-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating osteoclast differentiation, activation and bone resorption
|
|
EP2124999B1
(en)
|
2006-12-18 |
2012-10-03 |
Acceleron Pharma, Inc. |
Activin-actrii antagonists and uses for treating anemia
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
MX354099B
(es)
|
2007-02-01 |
2018-02-13 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
|
|
TWI432449B
(zh)
|
2007-02-02 |
2014-04-01 |
Acceleron Pharma Inc |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
KR20160129095A
(ko)
*
|
2007-02-09 |
2016-11-08 |
악셀레론 파마 인코포레이티드 |
액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
|
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
CA2699936A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
AU2008346956A1
(en)
|
2008-01-07 |
2009-07-16 |
Centocor, Ortho Biotech Inc. |
Method of treating erythropoietin hyporesponsive anemias
|
|
WO2009111793A2
(en)
|
2008-03-07 |
2009-09-11 |
Myoscience, Inc. |
Subdermal tissue remodeling using myostatin, methods and related systems
|
|
EP2318028B1
(en)
|
2008-06-26 |
2020-02-19 |
Acceleron Pharma Inc. |
Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
|
|
KR20220002710A
(ko)
|
2008-06-26 |
2022-01-06 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
|
PT2340031T
(pt)
|
2008-08-14 |
2019-07-25 |
Acceleron Pharma Inc |
Armadilhas de gdf para uso no tratamento de anemia
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
JP5611222B2
(ja)
|
2008-11-26 |
2014-10-22 |
アムジエン・インコーポレーテツド |
アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
|
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
|
CN102482339B
(zh)
|
2009-06-08 |
2015-06-17 |
阿塞勒隆制药公司 |
用于增加产热脂肪细胞的方法
|
|
EP2440577A4
(en)
|
2009-06-12 |
2013-01-23 |
Acceleron Pharma Inc |
SHORTEN ACTRIIB FC FUSION PROTEINS
|
|
RU2642302C1
(ru)
|
2009-08-13 |
2018-01-24 |
Акселерон Фарма Инк. |
Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
|
|
BR112012005225B8
(pt)
|
2009-09-09 |
2023-01-10 |
Acceleron Pharma Inc |
Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
|
|
WO2011056896A1
(en)
|
2009-11-03 |
2011-05-12 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
WO2011063018A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
US20120121576A1
(en)
|
2010-11-08 |
2012-05-17 |
Jasbir Seehra |
Actriia binding agents and uses thereof
|
|
US8501768B2
(en)
|
2011-05-17 |
2013-08-06 |
Hoffmann-La Roche Inc. |
Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
|
|
DK3875104T3
(da)
|
2011-10-17 |
2025-02-03 |
Acceleron Pharma Inc |
Sammensætninger til behandling af ineffektiv erytropoiese
|
|
EP2780368B1
(en)
|
2011-11-14 |
2018-01-03 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
AU2012364736A1
(en)
|
2011-12-19 |
2014-07-24 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
KR101995751B1
(ko)
|
2012-01-05 |
2019-07-03 |
주식회사 와이바이오로직스 |
Ｄｌｋ１ 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제
|
|
ES2663993T3
(es)
|
2012-05-17 |
2018-04-17 |
Paranta Biosciences Limited |
Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido
|
|
MA37761A1
(fr)
|
2012-06-11 |
2017-09-29 |
Amgen Inc |
Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
|
|
CN112957462A
(zh)
|
2012-10-24 |
2021-06-15 |
细胞基因公司 |
用于治疗贫血的方法
|
|
WO2014138485A1
(en)
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
AU2014228423A1
(en)
|
2013-03-15 |
2015-11-05 |
Amgen Inc. |
Myostatin antagonism in human subjects
|
|
EP2981822B1
(en)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
|
TW201920262A
(zh)
*
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
|
WO2015143403A1
(en)
|
2014-03-21 |
2015-09-24 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
|
|
AP2016009549A0
(en)
|
2014-04-18 |
2016-11-30 |
Acceleron Pharma Inc |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
EP3155008B1
(en)
|
2014-06-13 |
2020-08-26 |
Atara Biotherapeutics, Inc. |
Formulated receptor polypeptides and related methods
|
|
BR112016029226A2
(pt)
|
2014-06-13 |
2017-10-17 |
Acceleron Pharma Inc |
métodos e composições para o tratamento de úlceras
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
FI3227675T3
(fi)
|
2014-12-03 |
2023-05-25 |
Celgene Corp |
Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
AU2016246602B2
(en)
|
2015-04-06 |
2020-11-19 |
Acceleron Pharma Inc. |
Single-arm type I and type II receptor fusion proteins and uses thereof
|
|
MA41916A
(fr)
|
2015-04-06 |
2021-04-14 |
Acceleron Pharma Inc |
Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
|
|
RS61881B1
(sr)
|
2015-04-22 |
2021-06-30 |
Biogen Ma Inc |
Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
|
|
EP3294320A4
(en)
|
2015-05-13 |
2018-12-26 |
Celgene Corporation |
Treatment of beta-thalassemia using actrii ligand traps
|
|
EP4190805A3
(en)
|
2015-05-20 |
2023-08-16 |
Celgene Corporation |
In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
|
|
EP3370754A4
(en)
|
2015-11-04 |
2019-10-23 |
Acceleron Pharma Inc. |
METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
|
|
JP7072507B2
(ja)
|
2015-11-23 |
2022-05-20 |
アクセルロン ファーマ インコーポレイテッド |
眼の障害を処置するための方法
|
|
EP3420002A4
(en)
|
2016-02-22 |
2020-01-15 |
Acceleron Pharma Inc. |
ACTRII ANTAGONISTS FOR USE TO INCREASE IMMUNITY
|
|
RU2748278C2
(ru)
|
2016-07-15 |
2021-05-21 |
Акселерон Фарма Инк. |
Композиции и способы лечения легочной гипертензии
|
|
MX2019001043A
(es)
|
2016-07-27 |
2019-09-26 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de la mielofibrosis.
|
|
WO2018067740A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
JP7280182B2
(ja)
|
2016-10-05 |
2023-05-23 |
アクセルロン ファーマ インコーポレイテッド |
バリアントＡｃｔＲＩＩＢタンパク質およびその使用
|
|
JOP20190085A1
(ar)
|
2016-10-20 |
2019-04-17 |
Biogen Ma Inc |
طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
|
|
JP7051846B2
(ja)
|
2016-11-10 |
2022-04-11 |
ケロス セラピューティクス インコーポレイテッド |
アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
|
|
CN110461880A
(zh)
|
2016-11-10 |
2019-11-15 |
科乐斯疗法公司 |
Gdnf融合多肽及其使用方法
|
|
GB201620119D0
(en)
|
2016-11-29 |
2017-01-11 |
Pharmafox Therapeutics Ag |
Compounds
|
|
CN110494155A
(zh)
|
2017-02-01 |
2019-11-22 |
阿塞勒隆制药公司 |
用于提高免疫活性的TGFβ和ActRII拮抗剂
|
|
CN110603049A
(zh)
|
2017-02-06 |
2019-12-20 |
阿塞勒隆制药公司 |
用于治疗心力衰竭的组合物和方法
|
|
HUE068733T2
(hu)
|
2017-06-14 |
2025-01-28 |
Celgene Corp |
Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére
|
|
JP7258021B2
(ja)
*
|
2017-11-09 |
2023-04-14 |
ケロス セラピューティクス インコーポレイテッド |
アクチビンＩＩａ型受容体変異体を含む医薬組成物
|
|
KR20200109330A
(ko)
|
2018-01-12 |
2020-09-22 |
케로스 테라퓨틱스, 인크. |
액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
|
|
CA3098679A1
(en)
|
2018-05-09 |
2019-11-14 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
KR20220088699A
(ko)
|
2019-09-27 |
2022-06-28 |
디스크 메디슨, 인크. |
골수섬유증 및 관련 상태의 치료 방법
|
|
WO2021189010A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iib variants
|
|
KR20230004515A
(ko)
|
2020-03-20 |
2023-01-06 |
케로스 테라퓨틱스, 인크. |
액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
|
|
WO2021189006A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iia variants
|
|
WO2022072882A1
(en)
|
2020-10-02 |
2022-04-07 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
WO2022235620A1
(en)
|
2021-05-04 |
2022-11-10 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
WO2022271716A2
(en)
|
2021-06-21 |
2022-12-29 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii signaling inhibitors
|
|
JP2024532831A
(ja)
|
2021-08-19 |
2024-09-10 |
ケロス セラピューティクス インコーポレイテッド |
アクチビン受容体ｉｉ型シグナル伝達阻害剤を使用する方法
|
|
WO2024054985A2
(en)
|
2022-09-09 |
2024-03-14 |
Keros Therapeutics, Inc. |
Methods of administering an activin type iib variant
|
|
WO2024102906A2
(en)
|
2022-11-10 |
2024-05-16 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
WO2024238920A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
WO2024238950A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|